Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
BioNTech quietly drops Claudin6 work
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
